What’s Ahead for Achieve Life Sciences, Inc. (ACHV) After Today’s Big Decline?

The stock of Achieve Life Sciences, Inc. (NASDAQ:ACHV) is a huge mover today! The stock decreased 5.79% or $0.14 during the last trading session, reaching $2.28. About 108,406 shares traded. Achieve Life Sciences, Inc. (NASDAQ:ACHV) has declined 44.72% since September 11, 2018 and is downtrending. It has underperformed by 44.72% the S&P500.
The move comes after 6 months negative chart setup for the $15.18 million company. It was reported on Sep, 11 by Barchart.com. We have $2.19 PT which if reached, will make NASDAQ:ACHV worth $607,280 less.

Analysts await Achieve Life Sciences, Inc. (NASDAQ:ACHV) to report earnings on November, 6. They expect $-0.22 EPS, up 69.01 % or $0.49 from last year’s $-0.71 per share. After $-0.50 actual EPS reported by Achieve Life Sciences, Inc. for the previous quarter, Wall Street now forecasts -56.00 % EPS growth.

More notable recent Achieve Life Sciences, Inc. (NASDAQ:ACHV) news were published by: Benzinga.com which released: “31 Stocks Moving In Tuesday’s Pre-Market Session – Benzinga” on June 11, 2019, also Seekingalpha.com with their article: “Achieve Life Sciences, Inc. (ACHV) CEO Rick Stewart on Q2 2019 Results – Earnings Call Transcript – Seeking Alpha” published on August 08, 2019, Finance.Yahoo.com published: “Did You Manage To Avoid Achieve Life Sciences’s (NASDAQ:ACHV) Painful 55% Share Price Drop? – Yahoo Finance” on July 10, 2019. More interesting news about Achieve Life Sciences, Inc. (NASDAQ:ACHV) were released by: Seekingalpha.com and their article: “Achieve extends NIH collaboration to advance cytisinicline for smoking cessation – Seeking Alpha” published on July 23, 2019 as well as Finance.Yahoo.com‘s news article titled: “The Week Ahead In Biotech: Conference Presentations, IPO News Flow Take The Spotlight – Yahoo Finance” with publication date: September 08, 2019.

Achieve Life Sciences, Inc., a biopharmaceutical company, develops and commercializes therapies that address treatment resistance in cancer patients. The company has market cap of $15.18 million. It is developing Apatorsen to block the production of heat shock protein 27, a cell-survival protein expressed in various types of cancers, including bladder, prostate, breast, pancreatic, and non-small cell lung cancer. It currently has negative earnings.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.